The Food and Drug Administration on Monday announced plans to offer its employees a broader set of artificial intelligence tools to use in premarket reviews and for other purposes amid persistent concerns that the technology can behave unpredictably.
The agency touts in a release that staff will now be able to use “agentic AI capabilities” to assist with “meeting management, pre-market reviews, review validation, post-market surveillance, inspections and compliance and administrative functions.” Agentic AI broadly refers to systems that can complete multistep tasks autonomously. The announcement says that the agency is employing “guidelines — including human oversight — to ensure reliable outcomes.”
Asked for more details about these guidelines, Ben Nichols, an FDA spokesperson, wrote in an email that the “agentic AI tools are exploratory” and that the AI does not make regulatory decisions or replace human judgement. “All outputs from AI are reviewed and validated” by FDA staff “before being incorporated into any official regulatory action, ensuring that the AI remains a support tool rather than a decision maker,” he wrote. (The FDA’s drug center alone has lost over 1,000 staff this year through reductions in force and voluntary departures.)
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.